Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of aspirin in preparing anti-AIDs (Acquired Immune Deficiency Syndrome) drugs

An anti-AIDS and aspirin technology, applied in the new use of aspirin, the application in the preparation of anti-AIDS drugs, and the field of AIDS drug composition, can solve the problems of aspirin's anti-HIV effect and reports, and achieve good specificity and safety High, clear effect

Inactive Publication Date: 2014-04-16
FUDAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, so far, there is no report on the anti-HIV effect of aspirin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of aspirin in preparing anti-AIDs (Acquired Immune Deficiency Syndrome) drugs
  • Application of aspirin in preparing anti-AIDs (Acquired Immune Deficiency Syndrome) drugs
  • Application of aspirin in preparing anti-AIDs (Acquired Immune Deficiency Syndrome) drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1. The effect of the concentration of aspirin on HIV transcription inhibition

[0047] Prepare HIV pseudovirus carrying green fluorescent protein gene (pNL-4-3-EGFP) and infect Jurkat T cells, and screen stable strains of EGFP positive cells to establish a cell model of HIV pseudovirus infection. Cell culture conditions: RPMI 1640 medium plus 10% fetal bovine serum (FBS) and 1% double antibodies (penicillin and streptomycin), 37°C, 5% CO 2 Cell culture incubator. Aspirin was added to the cell culture medium at different concentrations of 2.5mM, 5mM, and 10mM. The cells were kept at 37℃, 5% CO 2 Cultivate in a cell incubator, at different time points, observe the expression of green fluorescent protein in the cells with a fluorescence microscope and take pictures. At the same time, the cells at different time points were collected, centrifuged at 1000 rpm for 5 min, washed once with 500 μL PBS, and resuspended with 200 μL PBS, and the percentage of GFP-positive cell...

Embodiment 2

[0049] Example 2. The effect of the duration of action of aspirin compounds on HIV transcription inhibition

[0050] To obtain a better activation concentration of the drug to treat the HIV-infected cell model, 1 day, 2 days, 3 days, 4 days after the drug treatment of HIV pseudovirus-infected cells, through the fluorescence microscope of the reporter gene green fluorescent protein Observe and detect by flow cytometry, analyze the inhibitory efficiency of HIV-infected cells, and obtain the time-effect relationship of drug action.

[0051] The results showed that over time, the number of green fluorescence-positive cells gradually decreased. After 96 hours of treatment with aspirin in the HIV-infected cell model, the proportion of green fluorescence-positive cells dropped to 12%, while the green fluorescence-positive cells in the HIV-infected cell model group were not treated with the drug. The proportion of cells is 98.7%. The results suggest that aspirin has a time-effect relation...

Embodiment 3

[0052] Example 3. Inhibition experiment of aspirin on HIV-1 replication in chronically infected H9 / HIV-1ⅢB cells.

[0053] Chronic infection H9 / HIV-1ⅢB cells originated from the NIH AIDS Research and Reference Reagent Program (Cat. No. 87). The drug antiviral experiment was carried out according to the method described in the literature (Wang RR, Gu Q, Yang LM, et a1. Anti-H1V-1 activities of extracts from the medicinal plant Rhus Chinensis. J Ethnopharmaco1.2006.105:269-73). The test drug is diluted in a 96-well micro-culture plate with complete medium, and each dilution is set to 3 wells, and each well is 100 μl. At the same time, a control well without drug and a positive control drug for zidovudine (AZT, purchased from Sigma) are set. Add 4×10 drops to each hole 8 / L 100μl of chronically infected cells HIV-1ⅢB / H9 cells. After culturing for 4 days, the supernatant was collected by centrifugation and inactivated by Triton X-100. The ELISA method measures the level of HIV-1 p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicine and relates to novel application of aspirin. The invention provides application of the aspirin in preparing anti-AIDs (acquired immune deficiency syndrome) drugs, and further provides an anti-AIDs drug composition containing the aspirin and application thereof. The anti-AIDs drug composition is suitable for HIV-1(human immunodeficiency virus-1) infection in every stage. Firstly, the effect of the aspirin is obvious, which is equivalent to congeneric clinical drug AZT (azidothymidine) which is used at present; secondly, the aspirin which is used as an NF-kappa B signal transduction inhibitor is not easy to generate drug resistance; thirdly, the aspirin has been in clinical use for many years, which is high in safety. Therefore, the invention provides a novel approach and a novel means for anti-HIV infection.

Description

Technical field [0001] The invention belongs to the field of biomedicine and relates to new uses of aspirin. Specifically, it relates to the application of aspirin in preparing anti-AIDS drugs, and also includes corresponding AIDS drug compositions and applications. Background technique [0002] Acquired immunodeficiency syndrome (AIDS) is an infectious disease caused by human immunodeficiency virus (HIV) infection that seriously endangers people's lives and health. According to WHO statistics, there are more than 40 million AIDS patients worldwide, with 5 million new patients every year, and about 3 million deaths each year. At present, the main clinical treatment method for AIDS is Highly active antiretroviral therapy (HAART), because it can effectively reduce the virus load (virus load) and protect the immune function, thereby correspondingly prolonging the HIV infection. Time to live. However, due to the current combination of reverse transcriptase inhibitors and protease ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/616A61K45/00A61P31/18
Inventor 朱焕章王鹏飞
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com